Empirical Wealth Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.06M | Buy |
44,042
+4,124
| +10% | +$108K | 0.02% | 390 |
|
|
2026
Q1 | $1.12M | Buy |
39,918
+6,049
| +18% | +$161K | 0.02% | 326 |
|
|
2025
Q4 | $843K | Sell |
33,869
-6,960
| -17% | -$176K | 0.02% | 363 |
|
|
2025
Q3 | $1.04M | Buy |
40,829
+13,274
| +48% | +$328K | 0.02% | 320 |
|
|
2025
Q2 | $668K | Sell |
27,555
-34
| -0.1% | -$793 | 0.02% | 378 |
|
|
2025
Q1 | $699K | Sell |
27,589
-19,169
| -41% | -$502K | 0.02% | 351 |
|
|
2024
Q4 | $1.24M | Buy |
46,758
+3,078
| +7% | +$83.5K | 0.03% | 257 |
|
|
2024
Q3 | $1.26M | Sell |
43,680
-2,151
| -5% | -$62.7K | 0.04% | 243 |
|
|
2024
Q2 | $1.28M | Buy |
45,831
+2,056
| +5% | +$56.6K | 0.04% | 233 |
|
|
2024
Q1 | $1.21M | Sell |
43,775
-7,364
| -14% | -$204K | 0.04% | 240 |
|
|
2023
Q4 | $1.47M | Sell |
51,139
-3,264
| -6% | -$98.7K | 0.05% | 201 |
|
|
2023
Q3 | $1.8M | Sell |
54,403
-6,191
| -10% | -$219K | 0.07% | 166 |
|
|
2023
Q2 | $2.22M | Sell |
60,594
-61,143
| -50% | -$2.38M | 0.09% | 148 |
|
|
2023
Q1 | $4.97M | Sell |
121,737
-1,871
| -2% | -$80.8K | 0.22% | 85 |
|
|
2022
Q4 | $6.33M | Buy |
123,608
+4,560
| +4% | +$219K | 0.3% | 68 |
|
|
2022
Q3 | $5.21M | Buy |
119,048
+20,303
| +21% | +$987K | 0.27% | 73 |
|
|
2022
Q2 | $5.18M | Buy |
98,745
+36,650
| +59% | +$1.87M | 0.27% | 70 |
|
|
2022
Q1 | $3.21M | Sell |
62,095
-1,275
| -2% | -$66.2K | 0.16% | 98 |
|
|
2021
Q4 | $3.74M | Buy |
63,370
+4,349
| +7% | +$215K | 0.19% | 88 |
|
|
2021
Q3 | $2.54M | Buy |
59,021
+2,671
| +5% | +$118K | 0.14% | 95 |
|
|
2021
Q2 | $2.21M | Buy |
56,350
+4,414
| +8% | +$172K | 0.13% | 106 |
|
|
2021
Q1 | $1.88M | Sell |
51,936
-23,213
| -31% | -$824K | 0.15% | 102 |
|
|
2020
Q4 | $2.77M | Buy |
75,149
+3,348
| +5% | +$123K | 0.21% | 67 |
|
|
2020
Q3 | $2.5M | Sell |
71,801
-533
| -0.7% | -$18.7K | 0.21% | 65 |
|
|
2020
Q2 | $2.24M | Buy |
72,334
+12,638
| +21% | +$429K | 0.21% | 70 |
|
|
2020
Q1 | $1.85M | Buy |
59,696
+4,143
| +7% | +$141K | 0.2% | 77 |
|
|
2019
Q4 | $2.06M | Buy |
55,553
+17,481
| +46% | +$623K | 0.23% | 69 |
|
|
2019
Q3 | $1.3M | Sell |
38,072
-5,729
| -13% | -$208K | 0.16% | 98 |
|
|
2019
Q2 | $1.8M | Buy |
43,801
+11,409
| +35% | +$453K | 0.23% | 67 |
|
|
2019
Q1 | $1.3M | Buy |
32,392
+3,506
| +12% | +$140K | 0.19% | 74 |
|
|
2018
Q4 | $1.2M | Buy |
28,886
+4,308
| +18% | +$179K | 0.2% | 66 |
|
|
2018
Q3 | $1.03M | Buy |
24,578
+7,065
| +40% | +$272K | 0.18% | 68 |
|
|
2018
Q2 | $603K | Buy |
17,513
+8,121
| +86% | +$278K | 0.11% | 96 |
|
|
2018
Q1 | $316K | Buy |
9,392
+1,899
| +25% | +$65.3K | 0.06% | 129 |
|
|
2017
Q4 | $257K | Sell |
7,493
-315
| -4% | -$10.7K | 0.06% | 127 |
|
|
2017
Q3 | $264K | Buy |
7,808
+286
| +4% | +$9.19K | 0.06% | 116 |
|
|
2017
Q2 | $240K | Sell |
7,522
-156
| -2% | -$4.92K | 0.06% | 117 |
|
|
2017
Q1 | $249K | Sell |
7,678
-800
| -9% | -$25.2K | 0.06% | 111 |
|
|
2016
Q4 | $261K | Buy |
8,478
+2,098
| +33% | +$64K | 0.06% | 110 |
|
|
2016
Q3 | $205K | Buy |
+6,380
| New | +$213K | 0.05% | 106 |
|
|
2016
Q1 | – | Sell |
-6,659
| Closed | -$204K | – | 109 |
|
|
2015
Q4 | $204K | Buy |
+6,659
| New | +$209K | 0.05% | 101 |
|
Other funds holding PFE
Empirical Wealth Management's PFE Position: Q2 2026 in Review
Empirical Wealth Management increased its Pfizer (PFE) stake by 10% in Q2 2026, buying an estimated $108K and bringing the position to 44,042 shares worth $1.06M. The position accounts for 0.02% of the portfolio, ranked #390.
Empirical Wealth Management first reported a position in PFE in Q4 2015 and has held it in 41 quarters since. The position peaked at $6.33M in Q4 2022. 2,104 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Empirical Wealth Management held 44,042 shares of Pfizer worth $1.06M as of Q2 2026.
- Empirical Wealth Management bought 4,124 Pfizer shares in Q2 2026, an estimated $108K.
- Pfizer made up 0.02% of Empirical Wealth Management's portfolio in Q2 2026, its #390 holding.
- Empirical Wealth Management first reported a position in Pfizer in Q4 2015 and has held it in 41 quarters since.
- Empirical Wealth Management's Pfizer position peaked at $6.33M in Q4 2022.
- 2,104 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Empirical Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.